Atreleuton
Product Specifications
Product Name Alternative
LCB01-0371
UNSPSC Description
Atreleuton (ABT-761) is a selective, reversible, and orally bioavailable 5-Lipoxygenase (5-LO) inhibitor. Atreleuton (ABT-761) exhibits potent and selective inhibition of leukotriene formation[1][2][3]. Atreleuton is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Target Antigen
Lipoxygenase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/atreleuton.html
Solubility
10 mM in DMSO
Smiles
O=C(N)N([C@H](C)C#CC1=CC=C(CC2=CC=C(F)C=C2)S1)O
Molecular Weight
318.37
References & Citations
[1]VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease. VIA Pharmaceuticals, Inc.|[2]Reid JJ, et al. ABT-761 (Abbott). Curr Opin Investig Drugs. 2001 Jan;2(1):68-71.|[3]Bell RL, et al. ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents. J Pharmacol Exp Ther. 1997 Mar;280(3):1366-73.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-117853/Atreleuton-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-117853/
Clinical Information
Phase 3
CAS Number
154355-76-7
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
